Patricia Puyol McKenna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Patricia Puyol McKenna has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim M. Banat
School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, UK
1 shared publication - James Stephen Gerard Dooley
University of Ulster
1 shared publication - Nigel George Ternan
Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, UK
1 shared publication - Patrick J. Naughton
Nutrition Innovation Centre for Food & Health (NICHE), Ulster University, Coleraine, BT52 1SA, UK
1 shared publication - Patrick Lemoine
Nanotechnology and Integrated Bioengineering Centre (NIBEC), School of Engineering, Ulster University, Belfast BT15 1ED, UK
1 shared publication
Latest Publications
- Open Access
- 22 January 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 138
Microbial Biosurfactants: Antimicrobial Activity and Potential Biomedical and Therapeutic Exploits
The rapid emergence of multidrug-resistant pathogens worldwide has raised concerns regarding the effectiveness of conventional antibiotics. This can be observed in ESKAPE pathogens, among others, whose multiple resistance mechanisms have led to a reduction in effective treatment options. Innovative strategies aimed at mitigating the incidence of antibiotic-resistant pathogens encompass the potential use of biosurfactants. These surface-active agents comprise a group of unique amphiphilic molecules of microbial origin that are capable of interacting with the lipidic components of microorganisms. Biosurfactant interactions with different surfaces can affect their hydrophobic properties and as a result, their ability to alter microorganisms’ adhesion abilities and consequent biofilm formation. Unlike synthetic surfactants, biosurfactants present low toxicity and high biodegradability and remain stable under temperature and pH extremes, making them potentially suitable for targeted use in medical and pharmaceutical applications. This review discusses the development of biosurfactants in biomedical and therapeutic uses as antimicrobial and antibiofilm agents, in addition to considering the potential synergistic effect of biosurfactants in combination with antibiotics. Furthermore, the anti-cancer and anti-viral potential of biosurfactants in relation to COVID-19 is also discussed.
- 22 January 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 138
Open AccessMicrobial Biosurfactants: Antimicrobial Activity and Potential Biomedical and Therapeutic Exploits
The rapid emergence of multidrug-resistant pathogens worldwide has raised concerns regarding the effectiveness of conventional antibiotics. This can be observed in ESKAPE pathogens, among others, whose multiple resistance mechanisms have led to a reduction in effective treatment options. Innovative strategies aimed at mitigating the incidence of antibiotic-resistant pathogens encompass the potential use of biosurfactants. These surface-active agents comprise a group of unique amphiphilic molecules of microbial origin that are capable of interacting with the lipidic components of microorganisms. Biosurfactant interactions with different surfaces can affect their hydrophobic properties and as a result, their ability to alter microorganisms’ adhesion abilities and consequent biofilm formation. Unlike synthetic surfactants, biosurfactants present low toxicity and high biodegradability and remain stable under temperature and pH extremes, making them potentially suitable for targeted use in medical and pharmaceutical applications. This review discusses the development of biosurfactants in biomedical and therapeutic uses as antimicrobial and antibiofilm agents, in addition to considering the potential synergistic effect of biosurfactants in combination with antibiotics. Furthermore, the anti-cancer and anti-viral potential of biosurfactants in relation to COVID-19 is also discussed.